Key Takeaways
- Extended-release injectable naltrexone has demonstrated comparable efficacy to buprenorphine for opioid use disorder in patients successfully detoxified, with adherence advantages due to monthly dosing.
- The COMBINE trial revealed that naltrexone with medical management reduces heavy alcohol use and improves abstinence rates, supporting its use as first-line pharmacotherapy.
- Digital therapeutics platforms including reSET-O have received FDA authorization based on clinical trial data showing improved abstinence rates when used as adjuncts to standard medication-assisted treatment.
- Emerging pharmacological targets for stimulant use disorder, including TAAR1 agonists and KOR antagonists, are showing promise in early-phase clinical trials where no approved medications currently exist.
- Combination pharmacotherapy trials demonstrate that pairing medications targeting different neurochemical systems may produce superior outcomes to monotherapy for complex cases.
- Trust SoCal stays current with clinical trial findings to ensure Orange County patients have access to the most effective evidence-based treatments available.
Introduction: Why Clinical Trials Are the Cornerstone of Evidence-Based Treatment
Clinical trials represent the highest standard of evidence in medicine, providing controlled conditions under which the safety and efficacy of treatments can be rigorously evaluated with minimal confounding. The randomized controlled trial (RCT), in which participants are randomly assigned to treatment or control conditions, is the primary design used to establish causal relationships between treatments and outcomes. In addiction medicine, clinical trials have been particularly important because the field has historically been plagued by treatments based on tradition, ideology, or anecdote rather than rigorous evidence. The proliferation of high-quality clinical trials over the past three decades has dramatically transformed the evidence base and enabled the identification of genuinely effective interventions.
The National Drug Abuse Treatment Clinical Trials Network (CTN), established by NIDA in 1999, has been central to advancing the clinical trial enterprise in addiction medicine. The CTN consists of more than forty research nodes affiliated with academic medical centers, each partnered with community-based treatment programs. This structure enables trials to be conducted in real-world clinical settings with diverse patient populations, enhancing the external validity of findings and facilitating rapid translation into practice. The CTN has completed more than thirty trials examining medications, behavioral therapies, and health services interventions, providing an extraordinary body of evidence on effective addiction treatment.
At Trust SoCal in Fountain Valley, our medical team regularly reviews published trial results and clinical guideline updates to ensure our Orange County patients receive treatments with the strongest available evidence. This commitment to evidence-based practice means that our protocols evolve as new trial data becomes available, rather than remaining static based on historical convention. We believe that patients deserve treatments proven to work, not those merely assumed to be helpful based on tradition. To discuss evidence-based treatment options, contact our team at (949) 280-8360.
Landmark Trials in Opioid Use Disorder Treatment
The NIDA-funded Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) trial, published in The Lancet in 2018, directly compared two of the most widely used medications for opioid use disorder in a randomized design. Among participants who successfully completed the induction phase, the trial found comparable efficacy between extended-release injectable naltrexone and sublingual buprenorphine-naloxone on opioid relapse outcomes. Critically, the trial identified a significant barrier to naltrexone initiation: participants randomized to naltrexone were substantially more likely to drop out before completing detoxification and beginning the medication, with a 28 percent dropout rate compared to 6 percent for buprenorphine. This finding has important clinical implications for patient selection and induction protocols.
The Suboxone Treatment and Recovery Trial (START), part of the NIDA CTN, examined whether extended buprenorphine-naloxone treatment lasting twenty-four weeks produced better outcomes than standard twelve-week treatment followed by taper. Results demonstrated that longer duration buprenorphine maintenance was associated with significantly higher rates of opioid abstinence at the end of the treatment period. These findings provided important support for the clinical practice of extended maintenance therapy rather than arbitrary time-limited treatment, challenging the historically prevalent but evidence-free practice of tapering medications after brief treatment periods.
The Prison-based Extended-Release Naltrexone trial demonstrated the remarkable impact of injectable naltrexone initiated in correctional settings. Participants randomized to receive extended-release naltrexone at the time of prison release had significantly lower rates of opioid relapse and overdose in the months following release compared to controls. These findings are particularly significant given the extremely high risk of overdose death in the days and weeks following incarceration, when tolerance is lost but cravings remain intense. Programs like Trust SoCal that work with justice-involved individuals can build on this evidence to address this high-risk transition period.
The FDA has approved three medications for opioid use disorder: methadone, buprenorphine, and naltrexone. Clinical trials consistently show these medications reduce mortality by 50-70%, yet fewer than one-third of specialty treatment programs offer all three options.
Key Opioid Use Disorder Trial Findings at a Glance
Recent clinical trials have clarified important questions about optimal medication use for opioid use disorder.
- X:BOT Trial: Extended-release naltrexone equivalent to buprenorphine in efficacy when induction is successful; buprenorphine has advantage for patients who cannot complete detoxification.
- START Trial: 24-week buprenorphine maintenance superior to 12-week with taper; supports extended treatment rather than arbitrary early discontinuation.
- Prison-Based Naltrexone Trial: Extended-release naltrexone initiated in prison reduces post-release overdose deaths; critical finding for corrections-based treatment programs.
- POATS Trial: Low-dose buprenorphine taper followed by naltrexone transition feasible for highly motivated patients with strong social support.
- Emergency Department Buprenorphine Study: Buprenorphine initiation in ED settings reduces opioid use and increases treatment engagement at 30 days compared to referral only.
Clinical Trial Evidence for Alcohol Use Disorder Treatments
The COMBINE study, the largest pharmacotherapy trial for alcohol use disorder ever conducted in the United States, enrolled 1,383 recently abstinent alcohol-dependent patients and tested naltrexone, acamprosate, and their combination, with or without a combined behavioral intervention. Published in JAMA in 2006, COMBINE found that naltrexone significantly reduced the risk of heavy drinking and increased days of abstinence compared to placebo, while acamprosate showed no significant benefit over placebo in this trial. The combined behavioral intervention enhanced outcomes when delivered with naltrexone, but did not add benefit when combined with acamprosate.
The Project MATCH trial examined whether matching patients to different behavioral therapies based on their clinical characteristics would improve outcomes compared to generic therapy assignment. Enrolling 1,726 patients across outpatient and aftercare settings, MATCH compared twelve-step facilitation therapy, cognitive-behavioral therapy, and motivational enhancement therapy. Findings showed that all three therapies produced substantial improvements in drinking outcomes, with few significant matching effects, suggesting that multiple behavioral approaches can be effective when delivered competently.
More recent trials have examined novel pharmacological approaches to alcohol use disorder, including gabapentin and topiramate. A double-blind placebo-controlled trial of gabapentin published in JAMA Internal Medicine found that gabapentin 1800 mg/day significantly increased rates of abstinence and reduced heavy drinking, and also improved sleep and mood symptoms during early recovery. While not FDA-approved for alcohol use disorder, this trial has contributed to growing evidence supporting gabapentin as an off-label option, particularly for patients who cannot tolerate or do not respond to first-line agents.
Clinical trial evidence supports combining FDA-approved medications with behavioral therapies for alcohol use disorder. The COMBINE trial demonstrated that naltrexone with medical management produces outcomes comparable to intensive behavioral therapy alone, offering a practical option for patients who prefer medication-focused care.
Digital Therapeutics and Technology-Based Treatment Trials
One of the most exciting recent developments in addiction treatment research is the emergence of digital therapeutics, software-based interventions that deliver evidence-based treatment content through smartphones and other digital platforms. The reSET clinical trial, conducted to support FDA De Novo authorization, enrolled 399 patients with substance use disorders and demonstrated that those receiving digital cognitive-behavioral therapy and contingency management via smartphone in addition to standard outpatient treatment achieved a thirty-six percent abstinence rate compared to seventeen percent for standard treatment alone. The reSET-O device, targeting opioid use disorder specifically, similarly demonstrated improved retention and abstinence outcomes in a multi-site trial.
Telehealth delivery of addiction treatment has been examined in several trials conducted during and after the COVID-19 pandemic, which necessitated rapid expansion of remote treatment services. A randomized trial published in JAMA Network Open found that buprenorphine initiation via telehealth produced outcomes equivalent to in-person initiation across multiple measures including treatment retention, opioid abstinence, and patient satisfaction. These findings have supported policy changes allowing telehealth prescribing of controlled substances for addiction treatment, dramatically expanding geographic access to evidence-based care.
Smartphone-based recovery support applications have been evaluated in several randomized trials examining their ability to extend the reach of therapeutic contact between sessions. A trial of the A-CHESS application for alcohol use disorder published in JAMA Internal Medicine found that patients assigned to receive the app in addition to standard discharge planning had significantly fewer risky drinking days over eight months of follow-up. These findings suggest that technology can meaningfully augment traditional treatment delivery, providing continuous support during the high-risk periods that characterize early recovery.
Evidence-Based Digital Interventions for Substance Use Disorders
Clinical trials have validated several technology-based approaches increasingly integrated into comprehensive addiction treatment programs.
- reSET and reSET-O (Pear Therapeutics): FDA-authorized prescription digital therapeutics demonstrating improved abstinence when added to standard treatment for substance and opioid use disorders.
- Telehealth Buprenorphine: Multiple trials confirm equivalent outcomes to in-person initiation, expanding access for rural and mobility-limited patients.
- A-CHESS Application: Reduced risky drinking days in randomized trial; provides continuous support through interactive tools, crisis resources, and social connection.
- Text Messaging Interventions: Several trials demonstrate that automated motivational text messages reduce substance use and increase engagement with treatment services.
- Internet-Delivered CBT: Randomized trials support online CBT delivery for alcohol and cannabis use disorders, with particular benefit for individuals facing geographic or scheduling barriers.
Emerging Pharmacological Targets: Trials on the Horizon
The absence of FDA-approved medications for stimulant use disorders represents the most significant unmet need in addiction pharmacotherapy. Multiple compounds have failed in late-stage clinical trials despite promising preclinical data. However, several emerging targets are generating genuine optimism. TAAR1 agonists, which modulate dopaminergic and glutamatergic transmission, have shown efficacy in reducing methamphetamine self-administration in primate models and have entered early-phase human trials, with initial safety data appearing favorable.
Kappa-opioid receptor (KOR) antagonists represent another promising pharmacological target that has entered clinical development for multiple substance use disorders. KOR antagonists block the activity of dynorphin, an endogenous opioid that produces dysphoria and contributes to the negative emotional states driving compulsive substance use and relapse. Early-phase trials have demonstrated acceptable safety profiles and signals of efficacy in reducing anxiety and stress-induced craving in humans. These compounds represent a mechanistically distinct approach to addiction pharmacotherapy that could address the negative reinforcement component of addiction that current medications do not adequately target.
Psychedelic-assisted therapies, while not yet FDA-approved for any addiction indication, have generated extraordinary scientific interest based on promising phase 2 clinical trial data. A randomized controlled trial of psilocybin-assisted therapy for alcohol use disorder published in JAMA Psychiatry found that psilocybin significantly reduced the percentage of heavy drinking days and increased abstinence rates compared to diphenhydramine control. Trust SoCal monitors this evolving literature carefully and will incorporate approved psychedelic-assisted therapies when they achieve regulatory approval and are supported by robust phase 3 evidence.
Applying Clinical Trial Evidence in Orange County Treatment
The clinical trial findings described throughout this article collectively represent a robust evidence base for addiction treatment that far exceeds what was available just twenty years ago. Translating this evidence into clinical practice requires systematic processes for identifying relevant trials, critically appraising their methodology and applicability to specific patient populations, and integrating new findings into clinical protocols in a thoughtful and timely manner. This evidence translation process is a core competency of high-quality addiction treatment programs.
At Trust SoCal, our medical and clinical team participates in continuing education, reviews peer-reviewed literature, and works within professional societies including the American Society of Addiction Medicine to stay current with trial findings and guideline updates. Our treatment protocols are reviewed annually and updated to reflect new evidence, ensuring that Orange County patients consistently have access to care reflecting the current state of addiction medicine.
The ongoing rapid evolution of addiction treatment science is reason for genuine optimism about the future of recovery. As clinical trials continue to identify new medications, refine existing therapies, and validate novel delivery modalities, the proportion of individuals who achieve sustained recovery should continue to increase. Trust SoCal remains committed to being at the forefront of evidence-based addiction care in Orange County. For a confidential consultation about your treatment options, contact us at (949) 280-8360 or visit us at 16537 Elm Cir, Fountain Valley, CA 92708.
Medical Review Board, MD, ABAM
Medical Director & Reviewer